Increased cellular cholesterol efflux in glycogen storage disease type Ia mice: A potential mechanism that protects against premature atherosclerosis  by Nguyen, Andrew D. et al.
FEBS 29840 FEBS Letters 579 (2005) 4713–4718Increased cellular cholesterol eﬄux in glycogen storage disease type
Ia mice: A potential mechanism that protects against
premature atherosclerosis
Andrew D. Nguyen, Chi-Jiunn Pan, Jeng-Jer Shieh, Janice Yang Chou*
Section on Cellular Diﬀerentiation, Heritable Disorders Branch, National Institute of Child Health and Human Development,
National Institutes of Health, Building 10, Room 9D42, NIH 9000, Rockville Pike, Bethesda, MD 20892, USA
Received 16 May 2005; revised 21 June 2005; accepted 18 July 2005
Available online 3 August 2005
Edited by Laszlo NagyAbstract Glycogen storage disease type Ia (GSD-Ia) patients
manifest a pro-atherogenic lipid proﬁle but are not at elevated
risk for developing atherosclerosis. Serum phospholipid, which
correlates positively with the scavenger receptor class B type I
(SR-BI)-mediated cholesterol eﬄux, and apolipoprotein A-IV
and E, acceptors for ATP-binding cassette transporter A1
(ABCA1)-mediated cholesterol transport, are increased in
GSD-Ia mice. Importantly, sera from GSD-Ia mice are more
eﬃcient than sera from control littermates in promoting SR-
BI- and ABCA1-mediated cholesterol eﬄuxes. As the ﬁrst step
in reverse cholesterol transport, essential for cholesterol homeo-
stasis, these observations provide one explanation why GSD-Ia
patients are apparently protected against premature atheroscle-
rosis.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Glycogen storage disease type Ia (GSD-Ia, MIM232200),
also known as von Gierke disease, is an autosomal recessive
disorder caused by a deﬁciency in glucose-6-phosphatase-a
(G6Pase-a) that catalyzes the hydrolysis of glucose-6-phos-
phate to glucose in the terminal step of glycogenolysis and glu-
coneogenesis [1,2]. Patients with GSD-Ia are unable to
maintain glucose homeostasis and present with growth retar-
dation, hypoglycemia, hepatomegaly, nephromegaly, hypertri-
glyceridemia, hypercholesterolemia, hyperuricemia, and lactic
acidemia [1,2]. The hypercholesterolemia is characterized by
an elevation of cholesterol in the low density lipoprotein
(LDL) and very low density lipoprotein (VLDL) fractions,
but a decrease in the high density lipoprotein (HDL) choles-Abbreviations: GSD-Ia, glycogen storage disease type Ia; SR-BI, sca-
venger receptor class B type I; ABCA1, ATP-binding cassette trans-
porter A1; G6Pase-a, glucose-6-phosphatase-a; HDL, high density
lipoprotein; LDL, low density lipoprotein; VLDL, very low density
lipoprotein; apo, apolipoptotein
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GSD-Ia responds only partially to therapeutic interventions
[4,5]. However, GSD-Ia patients are not found to exhibit endo-
thelial vascular dysfunctions [6] or have an elevated risk for the
development of atherosclerosis [7]. Why GSD-Ia patients are
seemingly protected against developing premature atheroscle-
rosis is currently unclear.
Reverse cholesterol transport, the removal of excess free
cholesterol from peripheral cells by HDL or its apolipopro-
teins and the subsequent delivery to the liver for excretion into
the bile, is a key step in maintaining cellular cholesterol
homeostasis (reviewed in [8,9]). The ﬁrst step in reverse choles-
terol transport is the eﬄux of unesteriﬁed cholesterol from
extrahepatic cells and its uptake by a cholesterol acceptor. In
addition to aqueous diﬀusion which occurs ineﬃciently with
all cell types, there are two principle mechanisms of cholesterol
eﬄux from peripheral cells to extracellular acceptors – those
mediated by the scavenger receptor class B type I (SR-BI)
and those mediated by the ATP-binding cassette transporter
A1 (ABCA1). The SR-BI mediates a bidirectional exchange
between the cell and cholesterol acceptors such as HDL and
lipid-rich apolipoproteins, and the direction of the net ﬂux
depends on the cholesterol gradient [10,11]. Studies have
shown that phospholipid (PL) is the major component of
HDL that modulates the SR-BI-mediated cellular cholesterol
eﬄux and HDL-PL levels best reﬂect the capacity of serum
to accept cellular cholesterol mediated by SR-BI [12,13]. Anal-
ysis of serum lipid proﬁle of GSD-Ia patients reveals that PL
levels are markedly increased [3,4]. In particular, the increase
in PL occurs primarily in the HDL fractions [4]. The ABCA1
mediates a unidirectional eﬄux of free cholesterol and PL from
the cell to lipid-poor apolipoproteins [14,15]. Apolipoptotein
A-I (apoA-I) [16], apoA-IV [17,18], and apoE [19] are the
key cholesterol acceptors (reviewed in [9,15]). Analysis of
serum apolipoprotein proﬁles of GSD-Ia patients reveals that
the levels of apoA-I are normal or slightly decreased, whereas
the levels of apoB, apoC-I, apoC-III, and apoE are increased
[20]. However, the levels of apoA-IV, which is protective
against atherogenesis [17,18], have not been investigated.
We had previously generated a G6Pase-a-deﬁcient (G6Pase-
a/) mouse line that manifests a phenotype virtually identical
to that of human GSD-Ia patients [21]. In this study, we show
that the lipid proﬁles of G6Pase-a/ mice also mimic those of
human GSD-Ia patients, including increased serum PL and
HDL-PL. Interestingly, apoA-IV levels are markedly higher
in the serum of G6Pase-a/ mice compared to the controlEuropean Biochemical Societies.
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lesterol eﬄux is an independent predictor of coronary artery
atherosclerosis [22], we evaluated the eﬃcacy of serum from
G6Pase-a/ mice to stimulate the eﬄux of cholesterol from
cells. We show that sera from G6Pase-a/ mice are more eﬃ-
cient than sera from the control littermates in promoting both
SR-BI- and ABCA1-mediated cellular cholesterol eﬄuxes.2. Materials and methods
2.1. G6Pase-a/ mice
All animal studies were conducted under an animal protocol ap-
proved by the NICHD Animal Care and Use Committee. A glucose
therapy was administered to the G6Pase-a/ mice [21] and weaned
mice were given unrestricted access to Mouse Chow (Zeigler Bros.,
Inc., Gardners, PA). Mouse serum samples were collected by retro-
orbital or tail vein bleeding in the morning prior to glucose injection.
For cholesterol eﬄux assays and HDL, HDL-PL, LDL, and VLDL
measurements, sera from 3 to 5 G6Pase-a/ mice were pooled to-
gether, and aliquots were stored at 80 C. GSD-Ia is an autosomal
recessive disorder and wild-type (G6Pase-a+/+) and heterozygous
(G6Pase-a+/) mice have virtually identical phenotype [21]. Thus, the
pooled sera from 3 to 5 G6Pase-a+/+ or G6Pase-a+/ littermates were
used as controls.
2.2. Lipid and lipoprotein analyses
Serum triglyceride and total cholesterol were analyzed using kits ob-
tained from Sigma Diagnostics, and serum HDL, LDL, and VLDL
cholesterol were measured using the Cholestech Lipid LDX system
(Hayward, CA). Serum total PL and HDL-PL contained in the super-
natants after precipitating the apoB-containing lipoproteins by dextran
sulfate-Mg2+ [23] were determined using a phospholipid assay kit
(Wako Diagnostics, Richmond, VA).
2.3. Preparation of recombinant apoA-IV and generation of
anti-apoA-IV serum
The entire coding region of human apoA-IV was isolated by RT-
PCR ampliﬁcation of human liver poly (A)+ RNA using oligonucleo-
tide primers derived from nucleotides 115 to 134 (5 0-ATGTTCC
TGAAGGCCGTGGT-3 0, sense) and nucleotides 1286 to 1305
(5 0-TCAGCTCTCAAAGGGGCCA-3 0, antisense) of Homo sapiens
apoA-IV mRNA (accession number NM_000482). The PCR product
was cloned into the pET-24a(+) vector (Novagen, Madison, WI) and
produced as a recombinant protein containing a 6xHis tag at the C-ter-
minus. Recombinant apoA-IV was aﬃnity puriﬁed on a nickel chelate
column, and used to raise antibodies in NZ white rabbits.
2.4. Western-blot analysis
For Western blot analysis, serum proteins were separated by electro-
phoresis through polyacrylamide–SDS gels and blotted onto polyvinyl-
idene ﬂuoride membranes (Millipore Co., MA). The membranes were
ﬁrst incubated with a rabbit antibody against mouse apoA-I, apoB,
apoC-I, apoC-III, or apoE obtained from Biodesign International
(Saco, ME), or a rabbit antibody against human apoA-IV. The
membranes were then incubated with goat anti-rabbit IgG antibody
and the immunocomplexes detected with the SuperSignal West Pico
kit obtained from Pierce (Rockford, IL).
2.5. Cellular cholesterol eﬄux assays
The SR-BI-mediated eﬄux was measured using Fu5AH rat hepa-
toma cells, that express high levels of the SR-BI [24] but lack the
ABCA1 [24,25], following the method of de la Llera Moya et al.
[26]. Fu5AH cells grown in Eagles minimal essential medium
(MEM) containing 5% fetal bovine serum (FBS) were seeded at
3 · 104 cells per well in 48-well plates (Corning, NY). After 48 h incu-
bation at 37 C, the cells were labeled for 72 h at 37 C in MEM-5%
FBS containing [1,2-3H]cholesterol (2 lCi/well, Amersham Biosci-
ences, Piscataway, NJ) and 2 lg/ml of the ACAT inhibitor
CP113,818. This ACAT inhibitor, which was present in all subsequent
treatments, ensures all labeled cholesterol exists as free cholesterol. Thewashed cells were then incubated for 18 h at 37 C in MEM containing
0.5% bovine serum albumin (BSA). Then cells in some wells were
dried, and extracted with isopropyl alcohol to provide a baseline
counts for total [1,2-3H]cholesterol content (T0). Cholesterol eﬄux
was determined in the remaining Fu5AH cells by incubating the cells
for 4 h in MEM containing 2.5% mouse serum samples. Eﬄux was per-
formed in triplicate and the percentage of radiolabeled cholesterol re-
leased (% eﬄux) was calculated as: (cpm in medium at 4h/T0) · 100.
The ABCA1-mediated cellular cholesterol eﬄux assay was per-
formed using J774 mouse macrophage cells that express very low levels
of the SR-BI [24] as described by Sakr et al. [27] with minor modiﬁca-
tions. Brieﬂy, J774 cells grown in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS (HI-FBS) were seeded at 1.4 · 105 cells
per well in 48-well plates. After 24 h incubation at 37 C, the cells were
labeled for 24 h at 37 C in medium containing 1% HI-FBS,
[1,2-3H]cholesterol (2 lCi/well), and 2 lg/ml of the ACAT inhibitor
CP113,818, which was present in all subsequent treatments. The
washed cells were incubated for 12–15 h at 37 C in RPMI containing
0.2% BSA in the absence or presence of 0.3 mM cpt-cAMP (Sigma),
which upregulates ABCA1 expression in J774 cells [27]. Then the con-
trol and cAMP-treated cells were incubated for 4 h in medium contain-
ing a cholesterol acceptor. The acceptors used were: human apoA-I
(Biodesign International), human apoA-IV, and serum samples from
G6Pase-a/ and control mice. ApoA-I in 10 mM NH4CO3, pH 7.4
and apoA-IV in 6 M guanidine HCl were extensively dialyzed against
a buﬀer containing 10 mM Tris–HCl, 150 mM NaCl, 1.0 mM EDTA,
pH 7.4 before use as acceptors. The percent eﬄux was calculated as de-
scribed for Fu5AH cells. The ABCA1-mediated eﬄux or the eﬄux
stimulated by cAMP was calculated as: 100 · (% eﬄux in the presence
of cAMP  % eﬄux in the absence of cAMP)/(% eﬄux in the absence
of cAMP). ApoA-I (20 lg/ml) and apoA-IV (20 lg/ml) were used as
positive controls for the ABCA1-mediated eﬄux and apoA-I was used
to normalize for variation among experiments. Statistical analysis
using the unpaired t-test was performed with Prism (GraphPad Soft-
ware, San Diego, CA). Data are presented as the means ± S.E.M.3. Results
3.1. G6Pase-a/ mice manifest a pro-atherogenic lipid proﬁle
We have previously shown that G6Pase-a/ mice manifest
a phenotype virtually identical to that of human GSD-Ia
patients [21], including hypercholesterolemia and hypertriglyc-
eridemia [1,2]. The mean serum cholesterol and triglyceride
levels in 3–4 week-old G6Pase-a/ mice under a glucose
therapy are 3.4- and 8.7-fold, respectively, higher than those
in the age-matched control animals (Fig. 1). One key diﬀerence
between cholesterol metabolism in mice and humans is that
mice lack the cholesteryl ester transfer protein that transfers
cholesteryl esters from HDL to LDL and VLDL fractions,
resulting in an increased HDL:LDL ratio compared to humans
(reviewed in [28]). In G6Pase-a/ mice, the HDL levels are
1.3-fold higher than those in the control littermates but LDL
and VLDL levels are markedly increased reaching 4.7- and
6.9-fold, respectively, of the levels in the G6Pase-a+/+/
G6Pase-a+/ mice (Fig. 1). Overall, the ratio of cholesterol
to HDL in G6Pase-a/ mice is 2.91 compared to 1.13 in the
control littermates (Fig. 1). Moreover, the ratios of HDL/
LDL and HDL/VLDL in G6Pase-a/ mice are markedly de-
creased, being 28% and 19%, respectively of the corresponding
values in the control littermates (Fig. 1). Taken together, the
G6Pase-a/ mice, like human GSD-Ia patients [3,4], manifest
a pro-atherogenic lipid proﬁle.
3.2. Serum PL and apolipoprotein proﬁles in G6Pase-a/ mice
In the SR-BI-mediated pathway, serum PL levels positively
correlate with the capacity of serum to accept cellular choles-
Fig. 1. Serum lipid proﬁles. (A) Serum levels of cholesterol, triglyceride, HDL, LDL, VLDL, PL, and HDL-PL. Cholesterol and triglyceride shown
are individual values from 3 to 4 week-old mice and HDL, LDL, VLDL, total PL, and HDL-PL shown are individual values from the seven separate
mouse serum pools. The mean is denoted by a horizontal bar. (s) G6Pase-a+/+/G6Pase-a+/ mice; (d) G6Pase-a/ mice. (B) Serum lipid levels and
ratios.
Fig. 2. Western blot analysis of serum apolipoprotein proﬁles. Serum
proteins from 1 to 4 week-old G6Pase-a+/+ (+/+), G6Pase-a+/ (+/),
and G6Pase-a/ (/) mice were electrophoresed through a 12%
(apoA-IV, apoA-I, and apoE), a 4–20% (apoC-I and apoC-III)
polyacrylamide–SDS gel, or a 3–8% (apoB) NuPAGE gel (Novex,
San Diego, CA) and transferred onto a PVDF membrane. The
immunocomplexes were detected as described under Section 2.
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els are 2.8- and 1.3-fold higher, respectively, than those in the
control subjects [4]. In G6Pase-a/mice, serum PL and HDL-
PL concentrations are 3.1- and 1.3-fold higher, respectively,
than those in the control littermates (Fig. 1), mimicking human
GSD-Ia patients.
In the ABCA1-mediated pathway, lipid-free or lipid-poor
apoA-I, apoA-IV, and apoE facilitate cholesterol transport
by acting as extracellular acceptors of free cholesterol and
PL [16–19]. In GSD-Ia patients, the serum levels of apoA-I
are normal or slightly decreased, whereas the levels of apoB,
apoC-I, apoC-III, and apoE are increased [20]. Serum apolipo-
protein proﬁles in G6Pase-a/ mice are similar to those re-
ported for human GSD-Ia patients. The apoA-I levels are
unchanged and apoB, apoC-I, apoC-III and apoE levels are in-
creased (Fig. 2). While serum apoA-IV levels in human GSD-
Ia patients have not been investigated, serum apoA-IV levels in
G6Pase-a/ mice are markedly higher than the levels in the
control littermates (Fig. 2).
3.3. Eﬄux of cholesterol from Fu5AH hepatoma cells to serum
of G6Pase-a/ mice
To measure the contribution of the SR-BI pathway we
examined cholesterol eﬄux from Fu5AH cells in response to
serum from G6Pase-a/ and G6Pase-a+/+/G6Pase-a+/ mice.
Fu5AH cells express high levels of SR-BI but lack ABCA1
[24,25]. Results in Fig. 3A show that cholesterol eﬄux from
Fu5AH cells is stimulated in a dose-dependent manner by ser-
um pooled from 3 week-old G6Pase-a/ and control mice.
However, the serum from G6Pase-a/ mice was consistently
more eﬃcient in promoting cholesterol eﬄux from Fu5AH
cells as compared to that of control littermates. The cholesterol
eﬄux from Fu5AH cells were then quantiﬁed using 2.5% of
mouse serum (Fig. 3B). A total of four independent serumpools obtained from 3–4 week-old G6Pase-a/ and control
littermates were studied. Again, the sera of G6Pase-a/ mice
are 1.59 ± 0.08 fold (P < 0.0001) more eﬃcient than the sera
from control mice in promoting cholesterol eﬄux from
Fu5AH cells.
3.4. Eﬄux of cholesterol from J774 macrophages to serum of
G6Pase-a/ mice
Two diﬀerent mechanisms operate in the eﬄux of cholesterol
from J774 cells – one driven by HDL and the other linked to
ABCA1 [29]. Because the ABCA1-mediated eﬄux in J774 cells
Fig. 3. Cholesterol eﬄux from Fu5AH hepatoma cells. (A) Dose–response relationship of cholesterol eﬄux from Fu5AH cells to serum of 3 week-
old control G6Pase-a+/+/G6Pase-a+/ (s) and G6Pase-a/ (d) mice. (B) Cholesterol eﬄux from Fu5AH cells to 2.5% of mouse serum. Four
independent serum pools of 3–4 week-old G6Pase-a/ mice and their control littermates were studied and data are presented as means ± S.E.M.
\P < 0.0001.
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gene [27], cholesterol eﬄux from J774 cells was measured both
in the absence and presence of cAMP. The eﬄux in the absence
of cAMP is a measure of the HDL-mediated pathway and the
diﬀerence in eﬄux between untreated and cAMP-treated cells
is a measure of the ABCA1 pathway [29].
We ﬁrst examined cholesterol eﬄux from J774 cells stimu-
lated by adding serum pooled from 3 week-old G6Pase-a/
and control littermates to a ﬁnal concentration ranging from
0.05% to 1.5%. The serum pools from G6Pase-a/ as well
as control animals promote cholesterol eﬄux from J774 cells
in a dose-dependent manner, both in the absence or presence
of cAMP (Fig. 4A). Again, serum pools from G6Pase-a/
mice are consistently 1.5- to 2.4-fold more eﬃcient in pro-
moting eﬄux compared to the control littermates (Fig. 4A).
Cholesterol eﬄux from J774 cells was further quantiﬁed using
0.5% of mouse serum. A total of four independent serum poolsFig. 4. Cholesterol eﬄux from J774 macrophages. (A) Dose–response relatio
G6Pase-a+/ (s) and G6Pase-a/ (d) mice. (B) Cholesterol eﬄux from J77
cAMP. Four independent serum pools from 3 to 4 week-old G6Pase-a/
presented as means ± S.E.M. The eﬄuxes to apoA-I (20 lg/ml) and apoA-IVobtained from 3 to 4 week-old G6Pase-a/ and control litter-
mates were studied. Results in Fig. 4B demonstrate that sera
from G6Pase-a/ mice are 1.571 ± 0.056 fold (P < 0.0001)
more eﬃcient than sera from control mice in promoting cho-
lesterol eﬄux from J774 cells in the absence of cAMP and
are 1.732 ± 0.401 fold (P < 0.02) more eﬃcient than sera from
control mice in promoting cholesterol eﬄux from J774 cells in
presence of cAMP. The results suggest that G6Pase-a/
mouse serum has an increased capacity to promote both
HDL- and ABCA1-mediated cellular cholesterol eﬄux.4. Discussion
GSD-Ia patients manifest a pro-atherogenic lipid proﬁle
characterized by hypercholesterolemia, hypertriglyceridemia,
reduced cholesterol in HDL, and increased cholesterol innship of cholesterol eﬄux to serum of 3 week-old control G6Pase-a+/+/
4 macrophages to 0.5% of mouse serum in the absence or presence of
mice and their age-matched control mice were studied and data are
(20 lg/ml) were used as controls. \P < 0.0001; \\P < 0.02.
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not at high risk for developing atherosclerosis [6,7]. One expla-
nation for this may be attributable to reverse cholesterol trans-
port. This process, which recycles cholesterol from peripheral
tissues to the liver, is protective against atherosclerosis and is
stimulated by HDL [8,9]. Using G6Pase-a/ mice, which
are a valid model of human GSD-Ia [21] and exhibit a typical
GSD-Ia pro-atherogenic lipid proﬁle, we examined this possi-
bility by measuring the eﬃcacy of sera from G6Pase-a/ mice
in promoting cellular eﬄux of free cholesterol, the ﬁrst step
in reverse cholesterol transport. We show that two major path-
ways of cholesterol eﬄux from peripheral cells, namely SR-BI
[10,11] and ABCA1 [14,15] mediated eﬄuxes, are more eﬃcient
in the presence of sera from G6Pase-a/ mice than sera of
control littermates. Since the potential of serum to promote
cellular cholesterol eﬄux is inversely correlated with athero-
sclerosis [22], our data provide one reason why GSD-Ia pa-
tients are apparently protected against developing premature
atherosclerosis.
The major determinants of the SR-BI-mediated cholesterol
eﬄux are levels of serum PL and HDL-PL [12,13]. Therefore,
the increases in PL and HDL-PL concentrations in sera of
G6Pase-a/ mice are one likely set of stimuli for the SR-BI-
mediated cholesterol eﬄux. In contrast, the ABCA1 mediates
the eﬄux of free cholesterol from the cell to lipid-poor apolipo-
proteins [14,15]. In both human [20] and mouse GSD-Ia,
serum apoA-I is unchanged or slightly decreased and apoE is
increased. We now show that serum apoA-IV levels in
G6Pase-a/ mice are markedly increased compared to those
in the control littermates, suggesting that the elevation of
apoA-IV and apoE may result in the enhancement of the
ABCA1-mediated cholesterol eﬄux.
SR-BI and ABCA1 are expressed primarily in the liver,
although both are also expressed to a lesser extent in macro-
phages [11,15]. Cholesterol accumulation in macrophages
leads to the formation of foam cells and atherosclerotic
lesions in vessel walls [8,9], so eﬃcient removal of excess cho-
lesterol from peripheral cells, such as the macrophages, is
important in preventing lesions. In the presence of a pro-
atherogenic lipid proﬁles, as in GSD-Ia, stimulation of the re-
verse cholesterol transport pathway could minimize the build
up of cholesterol in peripheral cells, reducing the risk of ath-
erosclerosis. There is some evidence for this mechanism. An
anti-atherogenic role of SR-BI has been demonstrated in mice
overexpressing the SR-BI gene [30–32]. Further support is de-
rived from bone marrow transplantation studies in mice.
ApoE-null [33] or LDL receptor-null [34] mice receiving the
SR-BI-null mouse bone marrow have an increased rate of
diet-induced atherosclerosis compared to SR-BI wild-type
bone marrow recipients. There is similar indirect evidence
for the role of ABCA1 in atherosclerosis. In both apoE-null
and LDL receptor-null mice, further knockout of the ABCA1
gene expression in macrophages signiﬁcantly enhances the
development of atherosclerosis [35] implying ABCA1 coun-
ters the atherogenic tendency. In support of this, ABCA1
was identiﬁed as the defective gene in Tangier disease, a se-
vere HDL deﬁciency syndrome characterized by accumula-
tion of cholesterol in tissue macrophages and prevalent
atherosclerosis [14].
The sera of G6Pase-a/ mice are more eﬃcient than sera of
control mice in promoting cholesterol eﬄux from J774 cells in
the absence of cAMP, which measures the HDL-mediatedpathway [29]. However, ABCA1 mediates primarily eﬄux of
cholesterol to lipid-poor apolipoproteins [14,15], and J774 cells
express very low levels of the SR-BI [24]. Recently, ABC trans-
porters ABCG1 and ABCG4 were shown to promote choles-
terol eﬄux from cells to HDL [36], raising the possibility
that the increased eﬃciency of G6Pase-a/ sera in promoting
cholesterol eﬄux from J774 cells in the absence of cAMP could
be mediated by ABCG1 and/or ABCG4.
In summary, while the precise mechanism(s) that lower the
atherogenic risk for hyperlipidemic GSD-Ia patients remains
unclear, our mouse data, taken with existing evidence, suggest
that an increased capacity to promote SR-BI- and ABCA1-
mediated cholesterol eﬄuxes may be important.
Acknowledgements: The authors gratefully acknowledge Dr. G.H.
Rothblat for gifts of J774 and Fu5AH cell lines, Pﬁzer for the gift of
the ACAT inhibitor CP113,818, and Dr. B.C. Mansﬁeld for critical
reading of the manuscript.References
[1] Chou, J.Y., Matern, D., Mansﬁeld, B.C. and Chen, Y.-T. (2002)
Type I glycogen storage diseases: disorders of the glucose-6-
phosphatase complex. Curr. Mol. Med. 2, 121–143.
[2] Chen, Y.T. (2001) Glycogen storage diseases in: The Metabolic
and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet,
W.S., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W. and
Vogelstein, B., Eds.), Eighth ed, pp. 1521–1551, McGraw-Hill
Inc., New York.
[3] Levy, E., Letarte, J., Lepage, G., Thibault, L. and Roy, C.C.
(1987) Plasma and lipoprotein fatty acid composition in glycogen
storage disease type I. Lipids 22, 381–385.
[4] Levy, E., Thibault, L.A., Roy, C.C, Bendayan, M., Lepage, G.
and Letarte, J. (1988) Circulating lipids and lipoproteins in
glycogen storage disease type I with nocturnal intragastric
feeding. J. Lipid Res. 29, 215–226.
[5] Fernandes, J., Alaupovic, P. and Wit, J.M. (1989) Gastric drip
feeding in patients with glycogen storage disease type I: its eﬀects
on growth and plasma lipids and apolipoproteins. Pediatr. Res.
25, 327–331.
[6] Lee, P.J., Celermajer, D.S., Robinson, J., McCarthy, S.N.,
Betteridge, D.J. and Leonard, J.V. (1994) Hyperlipidaemia does
not impair vascular endothelial function in glycogen storage
disease type 1a. Atherosclerosis 110, 95–100.
[7] Ubels, F.L., Rake, J.P., Slaets, J.P., Smit, G.P. and Smit, A.J.
(2002) Is glycogen storage disease 1a associated with atheroscle-
rosis. Eur. J. Pediatr. 161 (Suppl 1), S62–S64.
[8] Fielding, C.J. and Fielding, P.E. (2001) Cellular cholesterol eﬄux.
Biochim. Biophys. Acta 1533, 175–189.
[9] Yancey, P.G., Bortnick, A.E., Kellner-Weibel, G., de la Llera-
Moya, M., Phillips, M.C. and Rothblat, G.H. (2003) Importance
of diﬀerent pathways of cellular cholesterol eﬄux. Artherioscler.
Thromb. Vasc. Biol. 23, 712–719.
[10] Jian, B., de la Llera Moya, M., Ji, Y., Wang, N., Phillips, M.C.,
Swaney, J.B., Tall, A.R. and Rothblat, G.H. (1998) Scavenger
receptor class B type I as a mediateor of cellular cholesterol eﬄux
to lipoproteins and pohspholipid acceptors. J. Biol. Chem. 273,
5599–5606.
[11] Connelly, M.A. and Williams, D.L. (2004) Scavenger receptor BI:
a scavenger receptor with a mission to transport high density
lipoprotein lipids. Curr. Opin. Lipidol. 15, 287–295.
[12] Fournier, N., Paul, J.L., Atger, V., Cogny, A., Soni, T., de la
Llera-Moya, M., Rothblat, G. and Moatti, N. (1997) HDL
phospholipid content and composition as a major factor
determining cholesterol eﬄux capacity from Fu5AH cells to
human serum. Arterioscler. Thromb. Vasc. Biol. 17, 2685–
2691.
[13] Yancey, P.G., Kawashiri, M.A., Moore, R., Glick, J.M., Wil-
liams, D.L., Connelly, M.A., Rader, D.J. and Rothblat, G.H.
(2004) In vivo modulation of HDL phospholipid has opposing
4718 A.D. Nguyen et al. / FEBS Letters 579 (2005) 4713–4718eﬀects on SR-BI- and ABCA1-mediated cholesterol eﬄux. J.
Lipid Res. 45, 337–346.
[14] Lawn, R.M., Wade, D.P., Garvin, M.R., Wang, X., Schwartz, K.,
Porter, J.G., Seilhamer, J.J., Vaughan, A.M. and Oram, J.F.
(1999) The Tangier disease gene product ABCA1 controls the
cellular apolipoprotein-mediated lipid removal pathway. J. Clin.
Invest. 104, R25–R31.
[15] Oram, J.F. (2002) Tangier disease and ABCA1. Arterioscler.
Thromb. Vasc. Biol. 23, 720–727.
[16] Rye, K.A. and Barter, P.J. (2004) Formation and metabolism of
prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler.
Thromb. Vasc. Biol. 24, 421–428.
[17] Duverger, N., Tremp, G., Caillaud, J.M., Emmanuel, F., Castro,
G., Fruchart, J.C., Steinmetz, A. and Deneﬂe, P. (1996) Protec-
tion against atherogenesis in mice mediated by human apolipo-
protein A-IV. Science 273, 966–968.
[18] Cohen, R.D., Castellani, L.W., Qiao, J.H., Van Lenten, B.J.,
Lusis, A.J. and Reue, K. (1997) Reduced aortic lesions and
elevated high density lipoprotein levels in transgenic mice over-
expressing mouse apolipoprotein A-IV. J. Clin. Invest. 99, 1906–
1916.
[19] Curtiss, L.K. and Boisvert, W.A. (2000) Apolipoprotein E and
atherosclerosis. Curr. Opin. Lipidol. 11, 243–251.
[20] Alaupovic, P. and Fernandes, J. (1985) The serum apolipoprotein
proﬁle of patients with glucose-6-phosphatase deﬁciency. Pediatr.
Res. 19, 380–384.
[21] Lei, K.-J., Chen, H., Pan, C.-J., Ward, J.M., Mosinger, B., Lee,
E.J., Westphal, H. and Chou, J.Y. (1996) Glucose-6-phosphatase
dependent substrate transport in the glycogen storage disease type
1a mouse. Nat. Genet. 13, 203–209.
[22] Mikkola, T.S, Anthony, M.S., Clarkson, T.B. and St Clair, R.W.
(2003) Serum cholesterol eﬄux potential is an independent
predictor of coronary artery atherosclerosis. Atherosclerosis
170, 31–38.
[23] Warnick, G.R., Benderson, J. and Albers, J.J. (1982) Dextran
sulfate-Mg2+ precipitation procedure for quantitation of high-
density-lipoprotein cholesterol. Clin. Chem. 28, 1379–1388.
[24] Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M.L., Phillips, M.C.,
Rothblat, G.H., Swaney, J.B. and Tall, A.R. (1997) Scavenger
receptor BI promotes high density lipoprotein-mediated cellular
cholesterol eﬄux. J. Biol. Chem. 272, 20982–20985.
[25] Bortnick, A.E., Rothblat, G.H., Stoudt, G., Hoppe, K.L., Royer,
L.J., McNeish, J. and Francone, O.L. (2000) The correlation of
ATP-binding cassette 1 mRNA levels with cholesterol eﬄux from
various cell lines. J. Biol. Chem. 275, 28634–28640.
[26] de la Llera Moya, M., Atger, V., Paul, J.L., Fournier, N., Moatti,
N., Giral, P., Friday, K.E. and Rothblat, G. (1994) A cell culture
system for screening human serum for ability to promote cellularcholesterol eﬄux. Relations between serum components and
eﬄux, esteriﬁcation, and transfer. Arterioscler. Thromb. Vasc.
Biol. 14, 1056–1065.
[27] Sakr, S.W., Williams, D.L., Stoudt, G.W., Phillips, M.C. and
Rothblat, G.H. (1999) Induction of cellular cholesterol eﬄux to
lipid-free apolipoprotein A-I by cAMP. Biochim. Biophys. Acta
1438, 85–98.
[28] Barter, P.J., Brewer Jr., H.B., Chapman, M.J., Hennekens, C.H.,
Rader, D.J. and Tall, A.R. (2003) Cholesteryl ester transfer
protein: a novel target for raising HDL and inhibiting athero-
sclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160–167.
[29] Fournier, N., Atger, V., Paul, J.L., Sturm, M., Duverger, N.,
Rothblat, G.H. and Moatti, N. (2000) Human ApoA-IV overex-
pression in transgenic mice induces cAMP-stimulated cholesterol
eﬄux from J774 macrophages to whole serum. Arterioscler.
Thromb. Vasc. Biol. 20, 1283–1292.
[30] Arai, T., Wang, N., Bezouevski, M., Welch, C. and Tall, A.R.
(1999) Decreased atherosclerosis in heterozygous low density
lipoprotein receptor-deﬁcient mice expressing the scavenger
receptor BI transgene. J. Biol. Chem. 274, 2366–2371.
[31] Ueda, Y., Gong, E., Royer, L., Cooper, P.N., Francone, O.L. and
Rubin, E.M. (2000) Relationship between expression levels and
atherogenesis in scavenger receptor class B, type I transgenics. J.
Biol. Chem. 275, 20368–20373.
[32] Kozarsky, K.F., Donahee, M.H., Glick, J.M., Krieger, M. and
Rader, D.J. (2000) Gene transfer and hepatic overexpression of
the HDL receptor SR-BI reduces atherosclerosis in the choles-
terol-fed LDL receptor-deﬁcient mouse. Arterioscler. Thromb.
Vasc. Biol. 20, 721–727.
[33] Zhang, W., Yancey, P.G., Su, Y.R., Babaev, V.R., Zhang, Y.,
Fazio, S. and Linton, M.F. (2003) Inactivation of macrophage
scavenger receptor class B type I promotes atherosclerotic lesion
development in apolipoprotein E-deﬁcient mice. Circulation 108,
2258–2263.
[34] Covey, S.D., Krieger, M., Wang, W., Penman, M. and Trigatti,
B.L. (2003) Scavenger receptor class B type I-mediated protection
against atherosclerosis in LDL receptor-negative mice involves its
expression in bone marrow-derived cells. Arterioscler. Thromb.
Vasc. Biol. 23, 1589–1594.
[35] Aiello, R.J., Brees, D., Bourassa, P.A.K., Royer, L., Lindsey, S.,
Coskran, T., Haghpassand, M. and Francone, O.L. (2002)
Increased atherosclerosis in hyperlipidemic mice with inactivation
of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22,
630–637.
[36] Wang, N., Lan, D., Chen, W., Matsuura, F. and Tall, A.R. (2004)
ATP-binding cassette transporters G1 and G4 mediate cellular
cholesterol eﬄux to high-density lipoproteins. Proc. Natl. Acad.
Sci. USA 101, 9774–9779.
